Aspiration risk under anaesthesia: difference between revisions
Diff·revision 15 → 16·18:54, 17 Aug 2025
Difference between revision 15 and revision 16 of Aspiration risk under anaesthesia. 2 lines changed; the page grew by 304 bytes.
| Revision 15 — 06:43, 18 Jul 2025 ArcuateArt (talk) correct the percentage — source reports it per patient-year 4,377 bytes ±0 | Revision 16 — 18:54, 17 Aug 2025 Areapercent_Ayo (talk) add the pregnancy statement as attributed to the labelling 4,681 bytes +304 | ||
|---|---|---|---|
| 38 | That is a defensible way to handle a rare, severe, and mechanistically plausible risk, and it is worth stating explicitly rather than presenting the guidance as though it rested on demonstrated harm. | 38 | That is a defensible way to handle a rare, severe, and mechanistically plausible risk, and it is worth stating explicitly rather than presenting the guidance as though it rested on demonstrated harm. |
| 39 | 39 | ||
| + | 40 | Anyone using compounds of this class outside clinical supervision has, by definition, no clinician aware of the exposure — which is the practical difficulty this topic raises and which this wiki notes without advising on. Research-use compounds are not approved for human administration.{{r|ada2024}} | |
| + | 41 | ||
| 40 | == References == | 42 | == References == |
| 41 | {{reflist}} | 43 | {{reflist}} |